KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD.
暂无分享,去创建一个
Harold I Feldman | Tamara Isakova | Brad C Astor | C. Fox | B. Astor | H. Feldman | J. Lash | L. Inker | C. Peralta | M. Kurella Tamura | James P Lash | Carmen A Peralta | Lesley A Inker | T. Isakova | Chester H Fox | Manjula Kurella Tamura
[1] S. Yusuf,et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. , 2011, Kidney international.
[2] A. Levey. A decade after the KDOQI CKD guidelines. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[3] J. Coresh,et al. Short-term change in kidney function and risk of end-stage renal disease. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[4] J. Cohn,et al. Proteinuria, Chronic Kidney Disease, and the Effect of an Angiotensin Receptor Blocker in Addition to an Angiotensin-Converting Enzyme Inhibitor in Patients With Moderate to Severe Heart Failure , 2009, Circulation.
[5] K. Heathcote,et al. Prevalence and duration of exercise induced albuminuria in healthy people. , 2009, Clinical and investigative medicine. Medecine clinique et experimentale.
[6] J. Kaufman,et al. Age affects outcomes in chronic kidney disease. , 2007, Journal of the American Society of Nephrology.
[7] Norbert Lameire,et al. Notice , 2012, Kidney International Supplements.
[8] C. Price,et al. Cardiac troponin I concentration is commonly increased in nondialysis patients with CKD: experience with a sensitive assay. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[9] David C. Wheeler,et al. Notice , 2012, Kidney International Supplements.
[10] F. Dumler,et al. Prospective nutritional surveillance using bioelectrical impedance in chronic kidney disease patients. , 2005, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.
[11] Finlay MacKenzie,et al. How should proteinuria be detected and measured? , 2009, Annals of clinical biochemistry.
[12] H E de Wardener,et al. Effect of urinary extracts from salt-loaded man on urinary sodium excretion by the rat. , 1972, Kidney international.
[13] Brenda R. Hemmelgarn,et al. Notice , 2012, Kidney International Supplements.
[14] S. Balamuthusamy,et al. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. , 2008, American heart journal.
[15] W. G. Walker,et al. Plasma aldosterone regulation in anephric man. , 1973, Kidney international.
[16] C. Fraser,et al. Selecting the optimum specimen for assessing slight albuminuria, and a strategy for clinical investigation: novel uses of data on biological variation. , 1987, Clinical chemistry.
[17] Patrick D. Brophy,et al. KDOQI US commentary on the 2012 KDIGO (Kidney Disease: Improving Global Outcomes) clinical practice guideline for acute kidney injury , 2013 .
[18] Grant D. Huang,et al. Glucose control and vascular complications in veterans with type 2 diabetes. , 2009, The New England journal of medicine.
[19] B. Kasiske,et al. Evidence and outcomes in CKD. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[20] J. Lieske,et al. A reference system for urinary albumin: current status , 2013, Clinical chemistry and laboratory medicine.
[21] M. Landray,et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.
[22] Bertram L Kasiske,et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. , 2011, Kidney international.
[23] S. Schinner,et al. Effects of Intensive Glucose Lowering in Type 2 Diabetes , 2009 .
[24] M. Al-mallah,et al. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. , 2008, Journal of cardiac failure.
[25] K. Lipska,et al. Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency , 2011, Diabetes Care.
[26] Harold I Feldman,et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. , 2012, The New England journal of medicine.
[27] O. Djurdjev,et al. Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[28] K. Kalantar-Zadeh,et al. Paradoxical association between body mass index and mortality in men with CKD not yet on dialysis. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[29] Michael E. Miller,et al. Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.
[30] D. Meier,et al. Five policies to promote palliative care for patients with ESRD. , 2013, Clinical journal of the American Society of Nephrology : CJASN.
[31] Amy C. Dwyer,et al. Special Feature Critical and Honest Conversations: the Evidence behind the " Choosing Wisely " Campaign Recommendations by the American Society of Nephrology , 2012 .
[32] Jennifer MacRae,et al. Overview of the Alberta Kidney Disease Network , 2009, BMC nephrology.
[33] A. Khwaja. KDIGO Clinical Practice Guidelines for Acute Kidney Injury , 2012, Nephron Clinical Practice.
[34] J. Adamson,et al. Notice , 2012, Kidney International Supplements.
[35] A. Zanchetti,et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. , 2010, Journal of the American College of Cardiology.
[36] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.
[37] P. Peduzzi,et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. , 2013, The New England journal of medicine.
[38] Supplemental Tables,et al. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). , 2009, Kidney international. Supplement.
[39] A. Morsing,et al. GFR prediction from cystatin C and creatinine in children: effect of including body cell mass. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[40] R. Califf,et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. , 2008, American heart journal.
[41] Ethan M Balk,et al. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[42] Josef Coresh,et al. Cystatin C versus creatinine in determining risk based on kidney function. , 2013, The New England journal of medicine.
[43] Benjamin J. Epstein,et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure , 2007 .
[44] Y. Chan,et al. Natriuretic peptides in chronic kidney disease. , 2008, Clinical journal of the American Society of Nephrology : CJASN.
[45] A. Levey,et al. Assessing the progression of renal disease in clinical studies: effects of duration of follow-up and regression to the mean. Modification of Diet in Renal Disease (MDRD) Study Group. , 1991, Journal of the American Society of Nephrology : JASN.
[46] Mark Woodward,et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. , 2011, Kidney international.
[47] G. Beck,et al. The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease , 1994 .
[48] S. Sethi,et al. Estimating kidney function in a multiethnic Asian population with multiple filtration markers. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[49] T. Connor,et al. Renal handling of calcium and phosphate during mineralocorticoid "escape" in man. , 1972, Kidney international.
[50] R. Bilous,et al. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[51] Kdoqi Disclaimer. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[52] C. Price,et al. Cardiac troponins and renal function in nondialysis patients with chronic kidney disease. , 2005, Clinical chemistry.
[53] C. Anderson,et al. Adherence to a healthy lifestyle and all-cause mortality in CKD. , 2013, Clinical journal of the American Society of Nephrology : CJASN.
[54] Daniel W. Jones,et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.
[55] A. Go,et al. FGF23 induces left ventricular hypertrophy. , 2011, The Journal of clinical investigation.
[56] Daniel W. Jones,et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.
[57] Hans L. Hillege,et al. Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure , 2006, Circulation.
[58] Laura E. Clark,et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. , 2011, Kidney international.
[59] Bruce Kupelnick,et al. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease , 2004 .
[60] A. Moss. Revised dialysis clinical practice guideline promotes more informed decision-making. , 2010, Clinical journal of the American Society of Nephrology : CJASN.
[61] H. Wiemann,et al. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. , 2001, European journal of heart failure.
[62] J. Adamson,et al. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease , 2012 .
[63] M. Woodward,et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis , 2010, The Lancet.
[64] Sylvia Stracke,et al. CUBN is a gene locus for albuminuria. , 2011, Journal of the American Society of Nephrology : JASN.
[65] M. Murtaugh,et al. Associations of body size with metabolic syndrome and mortality in moderate chronic kidney disease. , 2007, Clinical journal of the American Society of Nephrology : CJASN.
[66] C. Whitney,et al. Use of 13‐Valent Pneumococcal Conjugate Vaccine and 23‐Valent Pneumococcal Polysaccharide Vaccine for Adults With Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP) , 2013, MMWR. Morbidity and mortality weekly report.
[67] Jackson T. Wright,et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). , 2014, JAMA.
[68] M. S. Kirkman,et al. Response to Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61 , 2011, Diabetes Care.
[69] Chris Jones,et al. Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[70] R. Foley,et al. Serum troponin T measurement in patients with chronic renal impairment predicts survival and vascular disease: a 2 year prospective study. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[71] A. Go,et al. Association of N-terminal pro-B-type natriuretic peptide with left ventricular structure and function in chronic kidney disease (from the Chronic Renal Insufficiency Cohort [CRIC]). , 2013, The American journal of cardiology.
[72] Lorien S. Dalrymple,et al. Chronic Kidney Disease and the Risk of End-Stage Renal Disease versus Death , 2010, Journal of General Internal Medicine.
[73] P. Stevens,et al. Does urinary tract infection cause proteinuria or microalbuminuria? A systematic review. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[74] E. Salpeter,et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. , 2003, The Cochrane database of systematic reviews.
[75] S. Schinner,et al. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes , 2009 .
[76] S. Yusuf,et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial , 2008, The Lancet.
[77] J. Griffith,et al. The Framingham predictive instrument in chronic kidney disease. , 2007, Journal of the American College of Cardiology.
[78] B. Eriksen,et al. The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. , 2006, Kidney international.
[79] E. Ellis,et al. Proteinuria in children. , 1991, The Journal of the Arkansas Medical Society.
[80] G. Beck,et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. , 1994, The New England journal of medicine.
[81] Tom Greene,et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.
[82] J. Coresh,et al. One-Year Change in Kidney Function Is Associated with an Increased Mortality Risk , 2012, American Journal of Nephrology.
[83] W. Hermann,et al. Results from post‐hoc analyses of the CIBIS II trial: effect of bisoprolol in high‐risk patient groups with chronic heart failure , 2001 .
[84] Satoko Nakamura,et al. Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[85] V. Moyer,et al. Screening for Chronic Kidney Disease: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.
[86] G. Beck,et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. , 2005, Kidney international.
[87] A. Macleod,et al. Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease- Mineral and Bone Disorder (CKD-MBD) , 2009 .
[88] J. Beizer,et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. , 2005, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.
[89] E. Schaeffner,et al. Two Novel Equations to Estimate Kidney Function in Persons Aged 70 Years or Older , 2012, Annals of Internal Medicine.